Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish
Source: SeekingAlpha
2026-03-04 14:05:10 ET
Investment Overview
The last time I covered Cogent Biosciences, Inc. ( COGT ) for Seeking Alpha, it was November 2025 , and the Waltham, Massachusetts based biotech company's shares were soaring, as the market digested data from its Phase 3 PEAK study of its lead candidate bezuclastinib, plus sunitinib in patients with imatinib-resistant or intolerant Gastrointestinal Stromal Tumors ("GIST")....
Read the full article on Seeking Alpha
For further details see:
Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish
Cogent Biosciences Inc Com
NASDAQ: COGT
COGT Trading
3.68% G/L:
$37.74 Last:
302,608 Volume:
$36.89 Open:
COGT Latest News
February 28, 2026 09:45:00 am
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
February 17, 2026 03:48:00 pm
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
February 17, 2026 12:58:58 pm
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
February 17, 2026 08:00:00 am
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
COGT Stock Data
$5,401,765,510
107,636,656
3.87%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
